Biologics and ConjugatesSep 25, 2026
Dual-Payload Conjugates: Addressing the CMC Challenges of a New Therapeutic Approach
Dual-payload conjugates—two mechanistically distinct payloads carried on a single targeting vehicle—represent the next technological frontier beyond conventional ADCs.
Biologics and ConjugatesSep 21, 2026
PMO Therapeutics: Technical Review and Manufacturing Platform Capabilities
This article offers a systematic overview of PMO drug technology covering underlying principles, manufacturing workflows, and therapeutic prospects.
Biologics and ConjugatesAug 27, 2026
Mechanistic Studies in Catalytic Process Development: Supporting Manufacturing Processes and Revealing New Reaction Pathways
Through a case study on loading-dependent chemoselectivity in amide reductions, we demonstrate how first-principles chemical understanding provides the scientific foundation necessary for robust, end-to-end commercial manufacturing control strategies
Biologics and ConjugatesJul 30, 2026
Antibody-Oligonucleotide Conjugates: From Conjugation Strategy to Purification and Analytical Control
Antibody-Oligo Conjugate (AOC), as an innovative targeted gene therapy biopharmaceutical, effectively integrates the targeting advantages of monoclonal antibodies and the gene regulatory functions of oligonucleotides, helping address key limitations in the inherent of traditional antibody drugs and nucleic acid drugs, and showing substantial clinical
Biologics and ConjugatesJun 25, 2026
FAQ: CMC Development Strategy for Oligonucleotides in AOCs
•How to reduce hydrolysis during SMCC conjugation? •Can SMCC conjugate after hydrolytic ring-opening? •How is OAR1 regulated during random SMCC conjugation? •Which strategy is preferred for siRNA linker conjugation: pre-annealing or post-annealing conjugation?
Biologics and ConjugatesJun 12, 2026
Biocatalysis Enables the Efficient Synthesis and Commercial Application of Unnatural Amino Acids (UAAs)
Biocatalysis is a pivotal enabler for the sustainable synthesis of unnatural amino acids. By integrating novel enzyme discovery, multi-enzyme cascades and chemo-enzymatic routes, Porton has established practical capabilities to address industry challenges in substrate specificity and enzyme stability. Moving forward, Porton remains dedicated to bridging the gap between laboratory innovation and industrial-scale application, providing customers with reliable, scalable and atom-efficient solutions for UAA production.
Biologics and ConjugatesMay 27, 2026
Dry Particle Coating for the Enhancement of API Flowability and Bulk Density
The mechanism of the dry particle coating and a short description of four coating techniques including comil, LabRAM, a high shear mixer and a jet mill are provided.
Biologics and ConjugatesMar 11, 2026
Optimization of Synthetic Process and Metal-Chelation Impurity Control Strategy for Complex Peptide-based RDCs
It fully demonstrates the strength of Porton's one-stop RDC service platform, excellent project management capabilities, and efficient production and operation.
Biologics and ConjugatesFeb 28, 2026
The Perfect Integration of Immobilized Enzymes and Flow Chemistry: A Powerful Booster for the Commercialization of Biocatalysis Technology
Adhering to Porton's core value of “Pursuing Excellence”, the Porton biocatalysis team has designated "enzyme immobilization technology and its industrialization" as a core strategic technology.
